Stock Track | Telix Pharmaceuticals Soars 5.02% Intraday on Strong Q1 Revenue and Reaffirmed Guidance

Stock Track

Apr 07

Telix Pharmaceuticals Ltd (TLX.AU) saw its stock price soar 5.02% during Tuesday's intraday trading session.

The significant upward movement follows the company's release of its unaudited Q1 2026 group revenue of US$230 million, representing an 11% increase from the previous quarter. Furthermore, Telix reaffirmed its full-year 2026 revenue guidance of US$950 million to US$970 million, signaling confidence in its ongoing performance.

Growth was particularly strong in the Precision Medicine segment, where Q1 revenue reached US$186 million, a 16% increase quarter-over-quarter, supported by the performance of its products Illuccix and Gozellix. The company also reiterated its research and development spending guidance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1132660061"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132660061\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132660061?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132660061","market":"us","top_or_hot":-1,"title":"Stock Track | Telix Pharmaceuticals Soars 5.02% Intraday on Strong Q1 Revenue and Reaffirmed Guidance","media":"Stock Track","content":"<p>Telix Pharmaceuticals Ltd (TLX.AU) saw its stock price soar 5.02% during Tuesday's intraday trading session.</p><p>The significant upward movement follows the company's release of its unaudited Q1 2026 group revenue of US$230 million, representing an 11% increase from the previous quarter. Furthermore, Telix reaffirmed its full-year 2026 revenue guidance of US$950 million to US$970 million, signaling confidence in its ongoing performance.</p><p>Growth was particularly strong in the Precision Medicine segment, where Q1 revenue reached US$186 million, a 16% increase quarter-over-quarter, supported by the performance of its products Illuccix and Gozellix. The company also reiterated its research and development spending guidance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Telix Pharmaceuticals Soars 5.02% Intraday on Strong Q1 Revenue and Reaffirmed Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Telix Pharmaceuticals Soars 5.02% Intraday on Strong Q1 Revenue and Reaffirmed Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-07 08:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Telix Pharmaceuticals Ltd (TLX.AU) saw its stock price soar 5.02% during Tuesday's intraday trading session.</p><p>The significant upward movement follows the company's release of its unaudited Q1 2026 group revenue of US$230 million, representing an 11% increase from the previous quarter. Furthermore, Telix reaffirmed its full-year 2026 revenue guidance of US$950 million to US$970 million, signaling confidence in its ongoing performance.</p><p>Growth was particularly strong in the Precision Medicine segment, where Q1 revenue reached US$186 million, a 16% increase quarter-over-quarter, supported by the performance of its products Illuccix and Gozellix. The company also reiterated its research and development spending guidance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1132660061","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132660061","pubTimestamp":1775520235,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Telix Pharmaceuticals Ltd (TLX.AU) saw its stock price soar 5.02% during Tuesday's intraday trading session.The significant upward movement follows the company's release of its unaudited Q1 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"个股赛道|Telix Pharmaceuticals盘中大涨5.02%，Q1营收强劲并重申指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1},"content_text":"Telix Pharmaceuticals Ltd (TLX.AU) saw its stock price soar 5.02% during Tuesday's intraday trading session.The significant upward movement follows the company's release of its unaudited Q1 2026 group revenue of US$230 million, representing an 11% increase from the previous quarter. Furthermore, Telix reaffirmed its full-year 2026 revenue guidance of US$950 million to US$970 million, signaling confidence in its ongoing performance.Growth was particularly strong in the Precision Medicine segment, where Q1 revenue reached US$186 million, a 16% increase quarter-over-quarter, supported by the performance of its products Illuccix and Gozellix. The company also reiterated its research and development spending guidance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}